Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02005601 · ClinicalTrials.gov registry record · Phase 4

Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?

A Phase 4 study of Total Knee Arthroplasty, sponsored by Hospital for Special Surgery, New York.

Completed
Registry status
Phase 4
Development phase
106
Enrollment target
1
Study location

NCT02005601: Completed Phase 4 study of Total Knee Arthroplasty, sponsored by Hospital for Special Surgery, New York.

NCT02005601 is a Phase 4 study of Total Knee Arthroplasty that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 106 participants, below the 291-participant average among 29 other Total Knee Arthroplasty trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02005601, a Phase 4 study of Total Knee Arthroplasty, has completed, sponsored by Hospital for Special Surgery, New York.

COMPLETED
Registry status
Phase 4
Development phase
106 participants
Enrollment target
1
Study location

Study Summary

We are investigating the impact of duloxetine ("Cymbalta"), a serotonin and norepinephrine reuptake inhibitor, on pain after total knee arthroplasty (TKA). Specifically, the investigators will determine whether duloxetine, 60 mg daily for 2 weeks, reduces pain scores 2 weeks after TKA.

Primary Outcome

When considering the pain in the knee in which you are having/had surgery, on a scale of 0-10, with 0 being no pain and 10 being pain as bad as you can imagine, how would you describe your level of pain in the last 24 hours during ambulation?

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Duloxetine 60mg

Study Locations (1)

New York

  • Hospital for Special Surgery - New York

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2013-11
Est. Completion 2015-08
Phase Phase 4

What the finished NCT02005601 record still lists

NCT02005601 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 291-participant average among 29 other Total Knee Arthroplasty trials with a reported enrollment target (64% lower).

The record links to 1 condition, with Total Knee Arthroplasty appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02005601 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02005601 about?

NCT02005601 is a clinical study titled "Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?". We are investigating the impact of duloxetine ("Cymbalta"), a serotonin and norepinephrine reuptake inhibitor, on pain after total knee arthroplasty (TKA). Specifically, the investigators will determine whether duloxetine, 60 mg daily for 2 weeks, reduces pain scores 2 weeks after TKA.

What is the current status of trial NCT02005601?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 106 participants. The study started on 2013-11. Estimated completion is 2015-08.

What conditions does trial NCT02005601 study?

This clinical trial studies the following conditions: Total Knee Arthroplasty.

What interventions are being tested in trial NCT02005601?

The interventions under investigation include: Placebo (DRUG), Duloxetine 60mg (DRUG).

Who is sponsoring clinical trial NCT02005601?

This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02005601 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Total Knee Arthroplasty

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02005601's enrollment target sits among peer trials

106 17th of 29 higher than 13 of 29 other Total Knee Arthroplasty trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Total Knee Arthroplasty trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03181048 · 106 participants · NA

    Clinical Trial of Concomitant Hip Arthroscopy During PAO

  • NCT04682158 · 106 participants · Phase 2

    Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

  • NCT04724018 · 106 participants · Phase 1

    Sacituzumab Govitecan Plus EV in Metastatic UC

  • NCT04798274 · 106 participants · NA

    Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02005601, the US trial registry maintained by the National Library of Medicine. NCT02005601 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.